| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,990,000 |
| Market
Cap: |
2.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.062 - $1.22 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1 |
1 |
1 |
1 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
20,788 |
20,788 |
353,058 |
410,690 |
| Total Sell Value |
$1,455 |
$1,455 |
$144,635 |
$250,581 |
| Total People Sold |
1 |
1 |
6 |
6 |
| Total Sell Transactions |
1 |
1 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-01 |
4 |
AS |
$15.21 |
$30,422 |
D/D |
(2,000) |
0 |
|
-12% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-01 |
4 |
OE |
$4.56 |
$9,120 |
D/D |
2,000 |
2,000 |
|
- |
|
| Orwin John A |
President & CEO |
• • – |
2020-03-17 |
4 |
B |
$12.79 |
$76,740 |
D/D |
6,000 |
6,000 |
2.81 |
11% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-03-02 |
4 |
AS |
$22.98 |
$360,984 |
D/D |
(15,000) |
0 |
|
-10% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-03-02 |
4 |
OE |
$4.56 |
$68,400 |
D/D |
15,000 |
15,000 |
|
- |
|
| Cavet Guy |
Chief Technical Officer |
• – – |
2020-02-25 |
4 |
AS |
$20.53 |
$146,538 |
D/D |
(7,100) |
87,758 |
|
8% |
|
| Cavet Guy |
Chief Technical Officer |
• – – |
2020-02-25 |
4 |
OE |
$4.56 |
$9,576 |
D/D |
2,100 |
94,858 |
|
- |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-02-03 |
4 |
AS |
$19.43 |
$294,768 |
D/D |
(15,000) |
0 |
|
-5% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-02-03 |
4 |
OE |
$4.56 |
$68,400 |
D/D |
15,000 |
15,000 |
|
- |
|
| Cavet Guy |
Chief Technical Officer |
• – – |
2020-01-27 |
4 |
AS |
$20.00 |
$200,000 |
D/D |
(10,000) |
92,758 |
|
13% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-01-24 |
4 |
AS |
$18.47 |
$92,346 |
D/D |
(5,000) |
0 |
|
13% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-01-24 |
4 |
OE |
$4.56 |
$22,800 |
D/D |
5,000 |
5,000 |
|
- |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-01-17 |
4 |
AS |
$14.83 |
$148,992 |
D/D |
(10,000) |
0 |
|
28% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-01-17 |
4 |
OE |
$4.56 |
$45,600 |
D/D |
10,000 |
10,000 |
|
- |
|
| Cavet Guy |
Chief Technical Officer |
• – – |
2020-01-17 |
4 |
AS |
$14.84 |
$103,065 |
D/D |
(6,919) |
102,758 |
|
28% |
|
| Cavet Guy |
Chief Technical Officer |
• – – |
2020-01-17 |
4 |
OE |
$5.16 |
$9,902 |
D/D |
1,919 |
109,677 |
|
- |
|
| Baker Julian |
10% Owner |
– – • |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,532,760 |
3,223,030 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
12,134 |
480,820 |
|
- |
|
| Atwood Brian G |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
8,791 |
49,654 |
|
- |
|
| Steinman Lawrence |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
8,405 |
258,405 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
75,315 |
97,808 |
|
- |
|
| Bill & Melinda Gates Foundation |
|
• • • |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,396,644 |
1,396,644 |
|
- |
|
| Robinson William Hewitt |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,990 |
9,990 |
|
- |
|
| Hadley Harbor Master Investors (cayman) Ii L.p. |
10% Owner |
– – • |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,934,255 |
1,934,255 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
715,306 |
715,306 |
|
- |
|
132 Records found
|
|
Page 5 of 6 |
|
|
